drug
TECVAYLI
updated 6mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
News(10)
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesJ&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.biopharma_dive · 14d ago
- J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absentWhile innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.biospace · 1mo ago
- Novartis wagers almost $8B on a Chinese biotech’s RNA drugsIn exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.biopharma_dive · 1mo ago
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 1mo ago
- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750MAfter inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.biospace · 2mo ago
- GSK doubles down on Chimagen with $750M multiple myeloma wagerGSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…fiercebiotech · 2mo ago
- Trailing rivals, AbbVie scores win with dual-acting myeloma drugThe drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.biopharma_dive · 2mo ago
- AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma studyAbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to…biospace · 2mo ago
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialAbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multip…fiercebiotech · 2mo ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that